| Characteristic . | Somapacitan (0.04 mg/kg/wk) . | Somapacitan (0.08 mg/kg/wk) . | Somapacitan (0.16 mg/kg/wk) . | Daily GH (0.034 mg/kg/d)a . |
|---|---|---|---|---|
| FAS, n | 14 | 15 | 14 | 14 |
| Male, % | 50.0 | 66.7 | 57.1 | 64.3 |
| Age, years | 5.8 (1.8) | 5.8 (1.8) | 6.1 (2.3) | 5.9 (2.0) |
| BMI, kg/m2 | 15.3 (1.1) | 14.6 (1.1) | 15.1 (1.2) | 15.6 (1.4) |
| Height SDS | −4.1 (1.9) | −3.5 (1.5) | −3.8 (2.0) | −3.4 (1.1) |
| HVSDS | −2.9 (1.9) | −1.8 (1.7) | −2.9 (1.8) | −3.1 (2.1) |
| GH peak, µg/L | 2.9 (2.2) | 3.6 (2.1) | 4.1 (2.4) | 4.0 (2.0) |
| IGF-I SDS | −2.5 (1.0) | −2.5 (0.8) | −2.0 (1.0) | −2.1 (0.7) |
| IGFBP-3 SDS | −2.3 (1.4) | −2.4 (1.2) | −1.6 (1.5) | −2.1 (1.4) |
| Bone age vs chronological age ratio | 0.47 (0.15) | 0.62 (0.18) | 0.60 (0.20) | 0.56 (0.15) |
| Characteristic . | Somapacitan (0.04 mg/kg/wk) . | Somapacitan (0.08 mg/kg/wk) . | Somapacitan (0.16 mg/kg/wk) . | Daily GH (0.034 mg/kg/d)a . |
|---|---|---|---|---|
| FAS, n | 14 | 15 | 14 | 14 |
| Male, % | 50.0 | 66.7 | 57.1 | 64.3 |
| Age, years | 5.8 (1.8) | 5.8 (1.8) | 6.1 (2.3) | 5.9 (2.0) |
| BMI, kg/m2 | 15.3 (1.1) | 14.6 (1.1) | 15.1 (1.2) | 15.6 (1.4) |
| Height SDS | −4.1 (1.9) | −3.5 (1.5) | −3.8 (2.0) | −3.4 (1.1) |
| HVSDS | −2.9 (1.9) | −1.8 (1.7) | −2.9 (1.8) | −3.1 (2.1) |
| GH peak, µg/L | 2.9 (2.2) | 3.6 (2.1) | 4.1 (2.4) | 4.0 (2.0) |
| IGF-I SDS | −2.5 (1.0) | −2.5 (0.8) | −2.0 (1.0) | −2.1 (0.7) |
| IGFBP-3 SDS | −2.3 (1.4) | −2.4 (1.2) | −1.6 (1.5) | −2.1 (1.4) |
| Bone age vs chronological age ratio | 0.47 (0.15) | 0.62 (0.18) | 0.60 (0.20) | 0.56 (0.15) |
Data are mean (SD) unless otherwise stated.
Abbreviations: BMI, body mass index; FAS, full analysis set (all children who were correctly randomized and received at least 1 dose of randomized treatment); HVSDS, height velocity SD score; IGFBP-3, IGF binding protein 3; SDS, SD score.
aEquivalent to 0.238 mg/kg/wk.
| Characteristic . | Somapacitan (0.04 mg/kg/wk) . | Somapacitan (0.08 mg/kg/wk) . | Somapacitan (0.16 mg/kg/wk) . | Daily GH (0.034 mg/kg/d)a . |
|---|---|---|---|---|
| FAS, n | 14 | 15 | 14 | 14 |
| Male, % | 50.0 | 66.7 | 57.1 | 64.3 |
| Age, years | 5.8 (1.8) | 5.8 (1.8) | 6.1 (2.3) | 5.9 (2.0) |
| BMI, kg/m2 | 15.3 (1.1) | 14.6 (1.1) | 15.1 (1.2) | 15.6 (1.4) |
| Height SDS | −4.1 (1.9) | −3.5 (1.5) | −3.8 (2.0) | −3.4 (1.1) |
| HVSDS | −2.9 (1.9) | −1.8 (1.7) | −2.9 (1.8) | −3.1 (2.1) |
| GH peak, µg/L | 2.9 (2.2) | 3.6 (2.1) | 4.1 (2.4) | 4.0 (2.0) |
| IGF-I SDS | −2.5 (1.0) | −2.5 (0.8) | −2.0 (1.0) | −2.1 (0.7) |
| IGFBP-3 SDS | −2.3 (1.4) | −2.4 (1.2) | −1.6 (1.5) | −2.1 (1.4) |
| Bone age vs chronological age ratio | 0.47 (0.15) | 0.62 (0.18) | 0.60 (0.20) | 0.56 (0.15) |
| Characteristic . | Somapacitan (0.04 mg/kg/wk) . | Somapacitan (0.08 mg/kg/wk) . | Somapacitan (0.16 mg/kg/wk) . | Daily GH (0.034 mg/kg/d)a . |
|---|---|---|---|---|
| FAS, n | 14 | 15 | 14 | 14 |
| Male, % | 50.0 | 66.7 | 57.1 | 64.3 |
| Age, years | 5.8 (1.8) | 5.8 (1.8) | 6.1 (2.3) | 5.9 (2.0) |
| BMI, kg/m2 | 15.3 (1.1) | 14.6 (1.1) | 15.1 (1.2) | 15.6 (1.4) |
| Height SDS | −4.1 (1.9) | −3.5 (1.5) | −3.8 (2.0) | −3.4 (1.1) |
| HVSDS | −2.9 (1.9) | −1.8 (1.7) | −2.9 (1.8) | −3.1 (2.1) |
| GH peak, µg/L | 2.9 (2.2) | 3.6 (2.1) | 4.1 (2.4) | 4.0 (2.0) |
| IGF-I SDS | −2.5 (1.0) | −2.5 (0.8) | −2.0 (1.0) | −2.1 (0.7) |
| IGFBP-3 SDS | −2.3 (1.4) | −2.4 (1.2) | −1.6 (1.5) | −2.1 (1.4) |
| Bone age vs chronological age ratio | 0.47 (0.15) | 0.62 (0.18) | 0.60 (0.20) | 0.56 (0.15) |
Data are mean (SD) unless otherwise stated.
Abbreviations: BMI, body mass index; FAS, full analysis set (all children who were correctly randomized and received at least 1 dose of randomized treatment); HVSDS, height velocity SD score; IGFBP-3, IGF binding protein 3; SDS, SD score.
aEquivalent to 0.238 mg/kg/wk.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
